Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials

Clinical Cancer Research

Volumn 17, Issue 20, 2011, Pages 6592-6599

  An, Ming Wen ^a,b   Mandrekar, Sumithra J ^b   Branda, Megan E ^b   Hillman, Shauna L ^b   Adjei, Alex A ^c   Pitot, Henry C ^b   Goldberg, Richard M ^d   Sargent, Daniel J ^b  

^a VASSAR COLLEGE   (United States)

^b MAYO CLINIC   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPT; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PEMETREXED; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RESEARCH; CANCER SIZE; CANCER THERAPY; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BIOMETRY; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 80054122239     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0822     Document Type: Article

References (18)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-5. (Pubitemid 39173511)
2. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
3. Zia MI, Siu LL, Pond GR, Chen EX. Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol 2005;23:6982-91.
4. Lavin PT. An alternative model for the evaluation of antitumor activity. Cancer Clin Trials 1981;4:451-7.
5. Pivot X, Thierry-Vuillemin A, Villanueva C, Bazan F. Response rates: a valuable signal of promising activity? Cancer J 2009;15:361-5.
6. Sargent D, Campbell M, Grothey A, Goldberg R. Overall and 12-week tumor response versus actual tumor measurements as predictors of overall survival in advanced colorectal cancer-findings from NCCTG N9741 [abstract]. In: Proceedings of the 2008 ASCO GI Meeting; 2008 Jan 25-27; Orlando, FL. ASCO; 2008. Abstract nr 446.
7. Lara P, Redman M, Kelly K, Edelman M, Williamson S, Crowley J, et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol 2008;26:463-7. (Pubitemid 351171700)
8. Bradbury P, Seymour L. Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated endpoint? Cancer J 2009;15:354-60.
9. Dhani N, Tu D, Sargent DJ, Seymour L, Moore MJ. Alternate endpoints for screening phase II studies. Clin Caner Res 2009;15:1873-82.
10. Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small-cell lung cancer. J Natl Cancer Inst 2007;99:1455-61.
11. Wang Y, Sung C, Dartois C, Ramchandani R, Booth BP, Rock E, et al. Elucidation of relationship between tumor size and survival in nonsmall- cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 2009;86:167-74.
12. Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP, Jorga K, et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 2009; 27:4103-8.
13. Ma CX, Nair S, Thomas S, Mandrekar SJ, Nikcevich DA, Rowland KM, et al. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5929-37.
14. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30. (Pubitemid 41095110)
15. Kim GP, Sargent DJ, Mahoney MR, RowlandKM Jr, Philip PA, Mitchell E, et al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol 2009;27:2848-54.
16. Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982;247:2543-6. (Pubitemid 12155954)
17. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87. (Pubitemid 26072233)
18. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2000;101: 1642-9.